Ipamorelin vs Sermorelin

Overview

Ipamorelin and Sermorelin are both studied as growth-hormone (GH) secretagogues, meaning each is reported to promote GH release from the anterior pituitary in research models. The key distinction studied in the literature is the receptor each engages. Ipamorelin is a synthetic pentapeptide that acts as a selective agonist at the growth hormone secretagogue receptor (GHS-R1a), the same receptor targeted by the endogenous hormone ghrelin. Sermorelin is a 29-residue peptide corresponding to the biologically active 1-29 fragment of human growth hormone-releasing hormone (GHRH), and it acts at a separate receptor, the GHRH receptor (GHRH-R).

Because the two compounds engage distinct receptors and distinct intracellular pathways, they are frequently contrasted in research and are also studied together as a combination intended to probe whether dual-pathway stimulation produces an interaction larger than either input alone. Ipamorelin was developed in the 1990s by Novo Nordisk (research code NNC 26-0161) and described as the first selective GH secretagogue (Raun et al., 1998). Sermorelin was the subject of clinical pharmacology decades earlier as a GHRH analogue and was approved by the US FDA in 1997 as a diagnostic and paediatric agent before the originator discontinued commercial production around 2008; it is discussed here strictly as a research reference compound.

Enhanced Research Compounds supplies both Ipamorelin and Sermorelin as lyophilised powders for in-vitro laboratory research only.

Molecular Profiles Compared

The two molecules differ markedly in size and class. Ipamorelin is a small five-residue peptide built on non-natural amino acids for stability and selectivity; Sermorelin is a much larger 29-residue peptide that reproduces the active N-terminal segment of native GHRH.

Both compounds are supplied as lyophilised powder at ≥98% HPLC purity for laboratory research use.

Mechanism: Ipamorelin (GHS-R1a)

Findings below are drawn from published in-vitro and animal-model research:

• Ghrelin-receptor agonism: Ipamorelin binds and activates GHS-R1a, the receptor for endogenous ghrelin. In the foundational characterisation it released GH with potency and efficacy comparable to the earlier peptide GHRP-6 in pituitary cell and animal models (Raun et al., 1998).
• Calcium-dependent signalling: GHS-R1a is a Gq/11-coupled receptor; activation is reported to drive phospholipase C, inositol-trisphosphate generation, and intracellular calcium mobilisation in somatotrophs, a pathway distinct from the cAMP route used by GHRH (Casanueva et al., 2008).
• Selectivity profile:A defining feature reported for Ipamorelin is that, unlike some earlier GH secretagogues, it did not stimulate ACTH or cortisol release at levels different from GHRH in the characterisation studies, which is why it was described as the first “selective” GH secretagogue (Raun et al., 1998).

Mechanism: Sermorelin (GHRH-R)

• GHRH-receptor agonism: Sermorelin reproduces the 1-29 N-terminal fragment of GHRH, reported as the shortest segment retaining the full GH-releasing activity of the native hormone. It binds the GHRH receptor on pituitary somatotrophs (Walker, 2006).
• cAMP-dependent signalling: The GHRH receptor is Gs-coupled; activation is described as raising intracellular cAMP and promoting GH synthesis and release, a mechanism separate from the calcium-driven GHS-R1a pathway.
• Short circulating half-life: Sermorelin is reported to be cleared rapidly, with a circulating half-life on the order of 11-12 minutes after subcutaneous or intravenous administration in the pharmacology literature, in contrast to long-acting GHRH analogues engineered for extended duration.
• Feedback-sensitive release: Because Sermorelin acts upstream at the GHRH receptor, the GH response it elicits remains subject to somatostatin negative feedback, a point discussed as distinguishing GHRH-axis stimulation from direct GH administration (Walker, 2006).

The Commonly Studied Combination

Because Ipamorelin and Sermorelin engage two different receptors, they are often examined together rather than as direct substitutes. The rationale studied in the literature is that a GHRH-receptor agonist and a ghrelin-receptor agonist activate complementary signalling pathways (cAMP versus calcium), and combined stimulation has been reported to produce a GH response larger than the sum of the individual responses in research settings (Bowers, 1998).

A notable mechanistic study reported that GHRH itself can interact with the ghrelin receptor GHS-R1a as a positive allosteric modulator, increasing the binding capacity of ghrelin rather than competing with it, which was proposed as one molecular basis for the synergy observed when GHRH-type and ghrelin-type peptides are applied together (Casanueva et al., 2008). For this reason a fixed pairing of a GHRH analogue with Ipamorelin is one of the most frequently studied secretagogue combinations. See the related CJC-1295 and Ipamorelin research reference for a long-acting GHRH-analogue pairing, and Tesamorelin for another stabilised GHRH-analogue studied in this class.

Key Published Research

Storage and Handling

Frequently Asked Questions